Abstract | BACKGROUND: METHODS AND RESULTS: One hundred and eight patients (mean age, 58.9 years) with AF lasting >or=48 h and <or=6 months were randomized to receive pilsicainide 50 mg t.i.d. (n=58) or placebo (n=50) for 2 weeks in a double-blinded fashion. All patients underwent appropriate anticoagulation therapy with warfarin for >or=3 weeks prior to the study enrolment or after verification of the absence of left atrial thrombi by transesophageal echocardiography. After 2 weeks of treatment, an electrocardiogram was recorded to determine whether sinus rhythm was restored. Sinus rhythm was restored in 22.4% of patients treated with pilsicainide and in 2% treated with placebo (p=0.002). Cardioversion was less likely to occur with oral pilsicainide when the AF duration exceeded 2 months or if the left atrial diameter exceeded 45 mm. There was no significant difference in the adverse cardiovascular event rate between the pilsicainide- and placebo-treated groups. One patient in the pilsicainide group developed an atrial flutter without any hemodynamic deterioration. CONCLUSION:
|
Authors | Kaoru Okishige, Masatake Fukunami, Koichiro Kumagai, Hirotsugu Atarashi, Hiroshi Inoue, Pilsicainide Suppression Trial for Persistent Atrial Fibrillation II Investigators |
Journal | Circulation journal : official journal of the Japanese Circulation Society
(Circ J)
Vol. 70
Issue 6
Pg. 657-61
(Jun 2006)
ISSN: 1346-9843 [Print] Japan |
PMID | 16723783
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Chemical References |
- Anti-Arrhythmia Agents
- Anticoagulants
- Warfarin
- Lidocaine
- pilsicainide
|
Topics |
- Administration, Oral
- Adult
- Aged
- Anti-Arrhythmia Agents
(administration & dosage, adverse effects)
- Anticoagulants
(administration & dosage)
- Atrial Fibrillation
(drug therapy)
- Contraindications
- Double-Blind Method
- Female
- Humans
- Lidocaine
(administration & dosage, adverse effects, analogs & derivatives)
- Male
- Middle Aged
- Recovery of Function
(drug effects)
- Remission Induction
- Thrombosis
(etiology, prevention & control)
- Warfarin
(administration & dosage)
|